Yull Arriaga

Pembrolizumab alone or combined with chemotherapy versus chemotherapy as first-line therapy for advanced urothelial carcinoma (KEYNOTE-361): a randomised, open-label, phase 3 trial

Thomas Powles, Tibor Csőszi, Mustafa Özgüroğlu et al. · The Lancet Oncology · 2021 · 648 citations · Full text

Medicine, Oncology, Pharmacology +11

HIF-2 Complex Dissociation, Target Inhibition, and Acquired Resistance with PT2385, a First-in-Class HIF-2 Inhibitor, in Patients with Clear Cell Renal Cell Carcinoma

Kevin D. Courtney, Yuanqing Ma, Alberto Diaz de Leon et al. · Clinical Cancer Research · 2019 · 184 citations · Full text

Medicine, Oncology, Pharmacology +16

Contemporary use of perioperative cisplatin‐based chemotherapy in patients with muscle‐invasive bladder cancer

Ganesh V. Raj, Saumil S Karavadia, Bruce J. Schlomer et al. · Cancer · 2010 · 144 citations · Full text

Medicine, Oncology, Surgery +13

Regorafenib for Patients with Metastatic Colorectal Cancer Who Progressed After Standard Therapy: Results of the Large, Single-Arm, Open-Label Phase IIIb CONSIGN Study

Eric Van Cutsem, Erika Martinelli, Stefano Cascinu et al. · The Oncologist · 2018 · 143 citations · Full text

Medicine, Oncology, Pharmacology +15

Phase II Trial of Neoadjuvant Systemic Chemotherapy Followed by Extirpative Surgery in Patients with High Grade Upper Tract Urothelial Carcinoma

Vitaly Margulis, Mäneka Puligandla, Edouard J. Trabulsi et al. · The Journal of Urology · 2019 · 133 citations · Full text

Medicine, Oncology, Urology +16